AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AGENUS INC Director's Dealing 2023

May 12, 2023

34023_dirs_2023-05-12_9ae0005b-e546-45f6-ad30-74a65ae2e612.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: MiNK Therapeutics, Inc. (INKT)
CIK: 0001840229
Period of Report: 2023-05-10

Reporting Person: AGENUS INC (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-05-10	Common Stock	P	22065	$1.509	Acquired	21617112	Direct
2023-05-11	Common Stock	P	23361	$1.4275	Acquired	21640473	Direct

Footnotes

F1: Open market purchases reported on this line occurred at a weighted average price of $1.509 (range of $1.47 to $1.54).

F2: Agenus Inc. undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.

F3: Open market purchases reported on this line occurred at a weighted average price of $1.4275 (range of $1.38 to $1.495).